This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This study is designed to assess the safety and efficacy of a 28-day treatment with Aztreonam Lysinate for Inhalation (AI, Cayston) and the ability of AI to maintain or improve clinical status following a 28-day course of Tobramycin Solution for Inhalation (TSI, TOBI) therapy in cystic fibrosis (CF) patients with pulmonary Pseudomonas aeruginosa (PA). The primary endpoint of this study is to evaluate the time to need for inhaled or IV antibotics.
Showing the most recent 10 out of 724 publications